EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Beam Therapeutics's Enterprise Value is $760.7 Mil.
Beam Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-182.9 Mil. Therefore, Beam Therapeutics's EV-to-FCF for today is -4.16.
The historical rank and industry rank for Beam Therapeutics's EV-to-FCF or its related term are showing as below:
BEAM'
s EV-to-FCF Range Over the Past 10 Years
Min: -95.76 Med: -3.87 Max: 67.43
Current: -4.16
During the past 7 years, the highest EV-to-FCF of Beam Therapeutics was 67.43. The lowest was -95.76. And the median was -3.87.
BEAM's EV-to-FCF is ranked worse than 100% of 394
companies
in the Biotechnology industry
Industry Median: 4.23
vs BEAM: -4.16
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Beam Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beam Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Beam Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's EV-to-FCF falls into.
Beam Therapeutics's current Enterprise Value is $760.7 Mil.
Beam Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-182.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Beam Therapeutics's PE Ratio for today is calculated as:
Beam Therapeutics's share price for today is $21.38.
Beam Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Beam Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Beam Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Beam Therapeutics (Beam Therapeutics) Business Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BEAM has been successfully added to your 